The Brown Laboratory pursues cutting-edge research focused on the treatment and prevention of breast cancer. This research is divided into three major areas:
Novel Targets for the Treatment of Triple-negative Breast Cancer
Using genomic, proteomic and metabolomic approaches, these projects focus on the identification of therapeutic compounds that are both more effective and less toxic for the treatment of ER-negative, PR-negative, HER2-negative, or “triple-negative”, breast cancers.
Identification and Targeting of Signaling Pathways Critical for the Prevention of ER-negative Breast Cancer
The prevention of breast cancer is a primary focus of research within the Brown Laboratory. The following projects utilize a broad range of techniques aimed at identifying novel chemopreventive agents for breast cancer.
Targeting Transcription Factors for the Prevention and Treatment of Breast Cancer
The identification of potential transcription factors critical for breast cancer development and growth is the focus of the third area of research within the Brown Laboratory. These projects center on determining the transcription factors that play key roles in the development of ER-negative and/or ER-positive breast cancers.